Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.
OBJECTIVE
To report outcomes of magnetic resonance imaging (MRI)-ultrasound fusion-targeted biopsy (MRF-TB) and 12-core systematic biopsy (SB) over a 26-month period in men with prior negative prostate biopsy.


METHODS
Between June 2012 and August 2014, 210 men presenting to our institution for prostate biopsy with ≥1 prior negative biopsy underwent multiparametric MRI followed by MRF-TB and SB and were entered into a prospective database. Clinical characteristics, maximum mpMRI suspicion scores (mSS), and biopsy results were queried from the database, and the detection rates of Gleason ≥7 prostate cancer (PCa) and overall PCa were compared between biopsy techniques using McNemar's test.


RESULTS
Forty seven (29%) of 161 men meeting inclusion criteria (mean age, 65 ± 8 years; mean prostate-specific antigen, 8.9 ± 8.9) were found to have PCa. MRF-TB and SB had overall cancer detection rates (CDRs) of 21.7% and 18.6% (P = .36), respectively, and CDR for Gleason score (GS) ≥7 disease of 14.9% and 9.3% (P = .02), respectively. Of 26 men with GS ≥7 disease, MRF-TB detected 24 (92.3%) whereas SB detected 15 (57.7%; P < .01). Using UCSF-CAPRA criteria, only 1 man was restratified from low risk to higher risk based on SB results compared to MRF-TB alone. Among men with mSS <4, 72% of detected cancers were low risk by UCSF-CAPRA criteria.


CONCLUSIONS
In men with previous negative biopsies and persistent suspicion of PCa, SB contributes little to the detection of GS ≥7 disease by MRF-TB, and avoidance of SB bears consideration. Based on the low likelihood of detecting GS ≥7 cancer and overall low-risk features of PCa in men with mSS <4, limiting biopsy to men with mSS ≥4 warrants further investigation.
School of Medicine, NYU Langone Medical Center, New York, NY.
Neil
N
Mendhiratta
Department of Urology, NYU Langone Medical Center, New York, NY.
Xiaosong
X
Meng
Department of Radiology, NYU Langone Medical Center, New York, NY.
Andrew B
AB
Rosenkrantz
Department of Urology, NYU Langone Medical Center, New York, NY.
James S
JS
Wysock
School of Medicine, NYU Langone Medical Center, New York, NY.
Michael
M
Fenstermaker
Department of Urology, NYU Langone Medical Center, New York, NY.
Richard
R
Huang
Department of Pathology, NYU Langone Medical Center, New York, NY.
Fang-Ming
FM
Deng
Department of Pathology, NYU Langone Medical Center, New York, NY.
Jonathan
J
Melamed
Department of Pathology, NYU Langone Medical Center, New York, NY.
Ming
M
Zhou
Department of Urology, NYU Langone Medical Center, New York, NY.
William C
WC
Huang
Department of Urology, NYU Langone Medical Center, New York, NY.
Herbert
H
Lepor
Department of Urology, NYU Langone Medical Center, New York, NY; Department of Radiology, NYU Langone Medical Center, New York, NY. Electronic address: samir.taneja@nyumc.org.
Samir S
SS
Taneja
D000368:Aged; D006801:Humans; D061705:Image-Guided Biopsy; D053783:Magnetic Resonance Imaging, Interventional; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D060787:Neoplasm Grading; D011467:Prostate / Q000000981:diagnostic imaging* / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology*; D012086:Reoperation; D018570:Risk Assessment; D018084:Ultrasonography, Interventional
D017430:Prostate-Specific Antigen